Print

B2B series webinar:

Raising Funds and Working as a Virtual Company

Virtual Event
Sept. 16
(on-demand access to this event included with registration for the webinar series)

register today icon

This webinar is part of a series of three educational events hosted in advance of the 2021 ARVO Bench to Bedside (B2B) Meeting. The other webinars included in the series are:

Series cost: Free for members, $15 nonmembers
(registration includes all three webinars, plus on-demand access if unable to attend a live presentation)

Description

It is important for bench scientists who innovate to learn how and when to communicate with stakeholders who can potentially help fund discoveries into marketable products, drugs and remedies that treat diseases that cause blindness. Following a period of strong financial results and investments in the ophthalmology space in 2019, most virtual startups have needed to pivot to prioritize other interests.

This webinar will help innovators and particularly those in virtual companies to ask questions and learn basic strategies and tactics to determine next steps in raising funds to sustain development. These will include the use of pitch decks and the identification of multiple funding platforms, including nondiluted government grants, private equity and co-licensing.

This webinar features a panel discussion from seasoned serial entrepreneurs. Attendees will be able to submit questions in advance and during the session. 


Moderator

image of Adrienne GravesAdrienne Graves, PhD
former CEO of Santen Inc

 

Adrienne Graves is a visual scientist by training and a global industry leader in ophthalmology. The former CEO of Santen Inc, Graves currently sits on the following corporate and nonprofit boards: Iveric Bio, Akorn, Nicox, Surface Pharmaceuticals, Oxurion, TherOptix, Greenbrook TMS, ASCRS Foundation, Glaucoma Research Foundation, AAO Foundation (Emeritus), Retina Global, Himalayan Cataract Project and the FFB RD Fund. She also co-founded OWL and Glaucoma 360. Graves received an AB from Brown University, a PhD in Psychobiology from the University of Michigan and she completed a postdoctoral fellowship in visual neuroscience at the University of Paris.

Speakers

image of David EvelethDavid Eveleth, PhD
CEO of Trefoil Therapeutics
 


David Eveleth, CEO of Trefoil Therapeutics, has over 30 years experience in the ophthalmic industry. He has raised more than $50 million across the spectrum of grants, angel, VC and public financing. Earlier in his career, Eveleth led the ophthalmology medicines development group at Pfizer. He has led or been involved in seven INDs, the approval of several new drugs and the approval of two medical devices. Eveleth has both biotech and pharmaceutical sector experience with several different companies across the neuroscience and ophthalmic therapeutic sectors. 

image of Eugene de JuanEugene de Juan, MD
ForSight Labs, LLC

 


Retinal surgeon, inventor, and entrepreneur Eugene de Juan, Jr., participates as inventor and advisor in early-stage ophthalmic opportunities. He holds over 120 patents and has authored over 250 previewed academic publications. de Juan completed his medical degree and internship training at the University of South Alabama College of Medicine. Before moving to San Francisco, he was a professor of ophthalmology at the University of Southern California, the co-director of Vitreoretinal Service at Wilmer Eye Institute at Johns Hopkins, director of the Microsurgery Advanced Design Laboratory and Joseph E. Green Professor of Ophthalmology. He was also a member of the medical staff of the Duke University Eye Center, holding joint teaching appointments with the departments of ophthalmology and cell biology. 

image of Alon HarrisAlon Harris, MS, PhD, FARVO
Vice Chair of International Research and Academic Affairs
Director of Ophthalmic Vascular Diagnostic & Research Program at Mount Sinai Hospital,
Icahn School of Medicine at Mount Sinai

Alon Harris is vice chair of international research and academic affairs and director of the Ophthalmic Vascular Diagnostic and Research Program at Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai. He is a world leading expert in the field of ocular blood flow, glaucoma risk factor assessment, imaging techniques for structural and functional glaucoma progression, ocular perfusion assessment, pharmaceutical interventions and mathematical modeling. Harris is one of three founders of AdOM and serves as a board member and consultant for various pharmaceutical, medical device, life sciences and startup companies.  

Organizer

Cheryl Rowe-RendlemanCheryl Rowe-Rendleman, PhD
CEO and Managing Consultant, Omar Consulting Group LLC

 

Dr. Cheryl Rowe-Rendleman is a clinical research and development professional, serving as CEO and Managing Consultant of Omar Consulting Group, LLC (Princeton NJ ǀ Durham, NC). Omar (ophthalmic management and research) is a practice that specializes in regulatory and clinical consulting for drugs and devices in the US, Europe, and China.  Cheryl attended public school in Baltimore, Maryland and graduated from Princeton University  where she studied chemical engineering and biology with a focus in neuroscience. Cheryl completed 2 postdoctoral training fellowships in developmental and degenerative eye diseases at respectively, the University of Texas and the University of San Francisco Medical Schools. She worked in industry for 13 years where she was responsible for driving research and development for different types of drugs and devices that treat diseases including those that cause blindness. She was named co-inventor on 3 US patents in ophthalmic drug delivery, has been involved in over 50 clinical trials, and published numerous manuscripts and books.

About Bench to Bedside

Discover the innovation and entrepreneurial spirit of ARVO Bench to Bedside (B2B)

Register for the B2B webinar series

Secure your spot for the three-part ARVO Bench to Bedside (B2B) webinar series

Organizing Committee

Meet the experts who are putting together the Bench to Bedside (B2B) Meeting

B2B in action

Learn how an academic startup became a $150 million public company